Health Condition 1: C719- Malignant neoplasm of brain, unspecified Health Condition 2: C719- Malignant neoplasm of brain, unspecified Health Condition 3: C700- Malignant neoplasm of cerebral meninges
Conditions
Interventions
Intervention1: Dexmedetomidine 0.4mcg/kg/hr and Dexmedetomidine 0.6mcg/kg/hr: 20ml of Drug Solution in infused with the infusion pump at the rate of 60ml/hr just before the skin closure of Neurosurgic
Sponsors
Rajendra institute of medical sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patient giving informed and written consent 2.ASA physical class 1 and 2 3.Patient of supratentorial space occupying lesion 4.Glasgow coma scale 15/15
Exclusion criteria
Exclusion criteria: 1.Patient refusal, not giving consent for study. 2.Pregnant and lactating women. 3.Patients undergoing elective surgical procedures in prone position including surgery of spine. 4.Patient having known case of allergy to dexmedetomidine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To observe the hemodynamic changes during tracheal extubation following two infusion doses of dexmedetomidine. To observe the airway response during tracheal extubationTimepoint: 30 minutes after completion of surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Time to emergence & time to tracheal extubation. 2.Early post operative complications such as coughing, laryngospasm, bronchospasm. 3.Adverse effects of the drug if any, such as delayed arousal, bradycardia & hypotension.Timepoint: 1 hour after tracheal extubation | — |
Countries
India
Contacts
Public ContactDr Vishwanath Kumar
Rajendra institute of medical sciences, Ranchi , Jharkhand
Outcome results
None listed